Abstract
Peter Doshi and colleagues describe their experience trying and failing to access clinical study reports from the manufacturer of Tamiflu and challenge industry to defend their current position of RCT data secrecy.
Publication types
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Antiviral Agents / adverse effects
-
Antiviral Agents / therapeutic use
-
Drug Industry* / ethics
-
Humans
-
Information Dissemination*
-
Oseltamivir / adverse effects
-
Oseltamivir / therapeutic use*
-
Outcome Assessment, Health Care*
-
Randomized Controlled Trials as Topic*
-
Review Literature as Topic*
Substances
-
Antiviral Agents
-
Oseltamivir